David M Williams1, Natasha Shrikrishnapalasuriyar2, Waheeba Syed2, Win L Yin2, Richard Chudleigh3, Stephen C Bain4, David E Price2, Jeffrey W Stephens5. 1. Department of Diabetes & Endocrinology, Morriston Hospital, Swansea SA6 6NL, United Kingdom; Diabetes Research Group, School of Medicine, Swansea University, Swansea SA2 8PP, United Kingdom. Electronic address: david.williams@doctors.org.uk. 2. Department of Diabetes & Endocrinology, Morriston Hospital, Swansea SA6 6NL, United Kingdom. 3. Department of Diabetes & Endocrinology, Singleton Hospital, Swansea SA2 8QA, United Kingdom. 4. Diabetes Research Group, School of Medicine, Swansea University, Swansea SA2 8PP, United Kingdom; Department of Diabetes & Endocrinology, Singleton Hospital, Swansea SA2 8QA, United Kingdom. 5. Department of Diabetes & Endocrinology, Morriston Hospital, Swansea SA6 6NL, United Kingdom; Diabetes Research Group, School of Medicine, Swansea University, Swansea SA2 8PP, United Kingdom.
Abstract
AIMS: Xultophy is the first fixed co-formulation pen containing insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide, authorized for type 2 diabetes patients since 2014. The aim was to review the clinical effectiveness of Xultophy across two hospitals in Wales. METHODS: Retrospective review of patients commenced on Xultophy between April 2016 and January 2018 was taken. Data related to glycemic control, weight and medication use were collected. RESULTS: Ninety-one patients were initiated on Xultophy, and 60 patients had follow-up for at least 6 months with a mean age of 57.3 years (47% male). Xultophy was well-tolerated, however, abdominal cramps and nausea limited use in three patients. Baseline HbA1c and weight were 84.7 mmol/mol and 101.5 kg. There were significant HbA1c reductions of 9.9 mmol/mol (p < 0.0001) and 13.4 mmol/mol (p < 0.008) at 6 and 12 months, and non-significant changes in weight. Patients with an HbA1c over 84 mmol/mol showed the greatest HbA1c improvement over 6-months. Those prescribed insulin prior to Xultophy had less significant improvements in HbA1c than those previously prescribed GLP-1 analogues. CONCLUSIONS: There were significant reductions in HbA1c and statistically insignificant weight gain over 12 months. Switching from GLP-1 analogues to Xultophy was associated with a greater HbA1c reduction compared to switching from insulin.
AIMS: Xultophy is the first fixed co-formulation pen containing insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide, authorized for type 2 diabetespatients since 2014. The aim was to review the clinical effectiveness of Xultophy across two hospitals in Wales. METHODS: Retrospective review of patients commenced on Xultophy between April 2016 and January 2018 was taken. Data related to glycemic control, weight and medication use were collected. RESULTS: Ninety-one patients were initiated on Xultophy, and 60 patients had follow-up for at least 6 months with a mean age of 57.3 years (47% male). Xultophy was well-tolerated, however, abdominal cramps and nausea limited use in three patients. Baseline HbA1c and weight were 84.7 mmol/mol and 101.5 kg. There were significant HbA1c reductions of 9.9 mmol/mol (p < 0.0001) and 13.4 mmol/mol (p < 0.008) at 6 and 12 months, and non-significant changes in weight. Patients with an HbA1c over 84 mmol/mol showed the greatest HbA1c improvement over 6-months. Those prescribed insulin prior to Xultophy had less significant improvements in HbA1c than those previously prescribed GLP-1 analogues. CONCLUSIONS: There were significant reductions in HbA1c and statistically insignificant weight gain over 12 months. Switching from GLP-1 analogues to Xultophy was associated with a greater HbA1c reduction compared to switching from insulin.
Authors: Alex Ramírez-Rincón; Carlos E Builes-Montaño; Jaime A Hincapié-García; Victor M Blanco; José F Botero-Arango Journal: Front Endocrinol (Lausanne) Date: 2022-04-28 Impact factor: 6.055